Skip to main content
Equibles
GERN logo

GERN · Geron Corp · Earnings Call Transcripts & Audio

Track GERN — free

Use GERN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GERN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.23 -0.01 (-0.81%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$809.52M
Shares
642.47M
Volume · Sep 30 9.44M Avg daily vol (3M) 10.27M

Geron Corp Earnings Call Transcripts

Quarterly earnings calls for Geron Corp (GERN), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲172.5% $297,000 −$41.05M '22 Q3 22-11-03 ▼90.1% $103,000 −$42.63M '22 Q4 23-03-16 ▼82.9% $21,000 −$38.12M '23 Q1 23-04-20 ▼60.3% $29,000 −$49.23M '23 Q2 23-08-03 ▼44.8% $164,000 −$44.80M '23 Q3 23-11-02 ▼77.7% $23,000 −$51.97M '23 Q4 24-01-08 ▲1347.6% $304,000 −$55.39M '24 Q1 24-05-02 ▲2941.4% $882,000 −$67.38M '24 Q2 24-08-08 ▲17138.4% $28.27M −$26.45M '24 Q3 24-11-07 ▲12927.3% $39.60M −$19.84M '25 Q1 25-05-07 ▲5459.6% $49.04M −$16.38M '25 Q2 25-08-06 ▲67.1% $47.23M −$18.43M '25 Q3 25-11-05 ▲30.9% $51.84M −$3.64M '26 Q1 26-05-06 LATEST ▲17.2% $57.48M −$16.68M '26 Q2 26-08-05
Conference
Investor event
2026-09-15
Geron Corp (GERN) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Geron Corp (GERN) Q2 2026 Earnings Call Transcript
Confident tone Ritello commercial performance and demand growth Real-world evidence and medical engagement Phase 3 IMpactMS trial in myelofibrosis
Revenue
$57.48M
▲ 17.2% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Geron Corp (GERN) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Geron Corp (GERN) Q1 2026 Earnings Call Transcript
Positive tone RYTELO U.S. commercial growth European commercial and pricing strategy Medical affairs / hematology engagement
Revenue
$51.84M
▲ 30.9% YoY
Diluted EPS
$-0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-13
Geron Corp (GERN) April 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-10
Geron Corp (GERN) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-25
Geron Corp (GERN) Q4 2025 Earnings Call Transcript
Confident tone Rytelo commercial growth and second-line MDS opportunity 3D surround sound and field force execution 2026 financial guidance and path to profitability
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Geron Corp (GERN) Q3 2025 Earnings Call Transcript
Positive tone RYTELO commercial performance and growth Healthcare provider awareness and education Commercial execution and strategy reset
Revenue
$47.23M
▲ 67.1% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Geron Corp (GERN) Q2 2025 Earnings Call Transcript
Positive tone RYTELO U.S. commercial performance HCP awareness and earlier-line adoption EU launch and partnering strategy
Revenue
$49.04M
▲ 5459.6% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Geron Corp (GERN) Q1 2025 Earnings Call Transcript
Positive tone RYTELO U.S. commercial launch IMPACT MS Phase 3 in myelofibrosis Commercial strategy enhancements
Revenue
$39.60M
▲ 12927.3% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Geron Corp (GERN) Q4 2024 Earnings Call Transcript
Positive tone RYTELO commercial launch and revenue trends Myelofibrosis IMpactMF Phase 3 trial Duration of treatment
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Geron Corp (GERN) Q3 2024 Earnings Call Transcript
Confident tone RYTELO U.S. Commercial Launch Performance Lower-Risk MDS Market Opportunity and Demand Financing Transactions and Capital Position
Revenue
$28.27M
▲ 17138.4% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Geron Corp (GERN) Q2 2024 Earnings Call Transcript
Confident tone RYTELO commercial launch NCCN Guidelines inclusion Lower-risk MDS market opportunity
Revenue
$882,000
▲ 2941.4% YoY
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Geron Corp (GERN) Q1 2024 Earnings Call Transcript
Confident tone U.S. Launch of Imetelstat in Lower-Risk MDS Market Differentiation and Unmet Need FDA / Regulatory Progress
Revenue
$304,000
▲ 1347.6% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Geron Corp (GERN) Q4 2023 Earnings Call Transcript
Confident tone FDA regulatory review and ODAC IMerge Phase 3 clinical data in lower-risk MDS IMpactMF Phase 3 in myelofibrosis
Revenue
$23,000*
▼ 77.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Geron Corp (GERN) Q3 2023 Earnings Call Transcript
Revenue
$164,000
▼ 44.8% YoY
Diluted EPS
$-0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Geron Corp (GERN) Q2 2023 Earnings Call Transcript
Revenue
$29,000
▼ 60.3% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-20
Geron Corp (GERN) Q1 2023 Earnings Call Transcript
Revenue
$21,000
▼ 82.9% YoY
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Geron Corp (GERN) Q4 2022 Earnings Call Transcript
Revenue
$103,000*
▼ 90.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Geron Corp (GERN) Q3 2022 Earnings Call Transcript
Revenue
$297,000
▲ 172.5% YoY
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Geron Corp (GERN) Q2 2022 Earnings Call Transcript
Revenue
$73,000
▼ 31.8% YoY
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-13
Geron Corp (GERN) Q1 2022 Earnings Call Transcript
Revenue
$123,000
▼ 10.2% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Geron Corp (GERN) Q4 2021 Earnings Call Transcript
Revenue
$1.04M*
▲ 1980% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Geron Corp (GERN) Q3 2021 Earnings Call
Revenue
$109,000
▲ 0.9% YoY
Diluted EPS
$-0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Geron Corp (GERN) Q2 2021 Earnings Call Transcript
Revenue
$107,000
▲ 148.8% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Geron Corp (GERN) Q1 2021 Earnings Call Transcript
Revenue
$137,000
▲ 163.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Geron Corp (GERN) Q4 2020 Earnings Call Transcript
Revenue
$50,000*
▼ 70.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Geron Corp (GERN) Q3 2020 Earnings Call Transcript
Revenue
$108,000
▼ 17.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Geron Corp (GERN) Q2 2020 Earnings Call Transcript
Revenue
$43,000
▼ 57.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-28
Geron Corp (GERN) Q1 2020 Earnings Call Transcript
Revenue
$52,000
▼ 8.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–30 of 30 earnings calls
Key facts CIK 886744 CUSIP 374163103 13F (30d) 7 filings 7 filers Visit website Investor relations